BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 14, 2023
Finance

Oct. 13 Quick Takes: Pfizer trims guidance, cutting costs by $3.5B due to COVID product sales

Plus: FDA approves Pfizer’s ulcerative colitis therapy from Arena deal and updates from Lilly, Novo, Harmony and more
BioCentury | Feb 23, 2021
Product Development

Meniere disease pipeline: Data Byte

Otonomy’s negative Phase III readout calls into question the utility of targeting the glucocorticoid receptor to treat Meniere disease.  There are no approved drugs to treat the disorder,
BioCentury | Dec 31, 2020
Distillery Therapeutics

Histamine receptor activation to treat anxiety and OCD

DISEASE CATEGORY: Neurology
INDICATION: Anxiety; obsessive compulsive disorder (OCD) Activation of histamine receptor HRH3 in the nucleus accumbens region of the brain could treat anxiety and OCD.
BioCentury | Dec 1, 2017
Clinical News

Auris misses in Phase III hearing loss trial

BioCentury | Oct 13, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

BioCentury | Oct 6, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

BioCentury | Dec 7, 2015
Clinical News

Wakix pitolisant regulatory update

Items per page:
1 - 10 of 43